Melanoma Panel
Use
This test is designed for individuals who have a clinical or suspected diagnosis of hereditary malignant melanoma or a family history of multiple primary melanomas. It is also applicable to those with a personal or family history of melanoma diagnosed at a young age or in conjunction with other related cancers such as pancreatic, renal, bladder, gastrointestinal, breast, astrocytoma, uveal melanoma, and mesothelioma. This genetic test helps in identifying gene mutations that could indicate a higher risk for melanoma and related cancers, providing valuable information for clinical decision-making regarding prevention and management strategies.
Special Instructions
STAT testing is available with a surcharge of 25%, which will not apply if the report is delivered after 16 days and a blood sample was submitted. Institutional pricing is available upon signing in. Specimens can be submitted via blood, buccal swap, saliva, or tissue. Orders can be faxed using the test requisition form provided if online ordering is not utilized.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration. The performance characteristics have been validated by PreventionGenetics following CAP and CLIA regulations. It is crucial to provide detailed clinical information as the ability to interpret variants is directly correlated with the quality of clinical data provided. There might be limitations in detecting all types of mutations, and not all mutations may have clinical significance identified. Variants of unknown significance may be reported, requiring clinical correlation.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7-16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided